Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma
Sintilimab plus lenvatinib showed heterogeneous efficacy in HCC. High <i>LINC01554</i> expression, elevated CD4+ Tcm cells, and solitary tumors may serve as predictive biomarkers for prolonged disease control.
Authors
- Yong Cui (ORCID: https://orcid.org/0000-0002-3658-1770)
- Hongwei Wang (ORCID: https://orcid.org/0000-0002-5571-7688)
- Ke-Min Jin
- Lijun Wang (ORCID: https://orcid.org/0000-0002-3686-6098)
- Ming Liu (ORCID: https://orcid.org/0000-0001-9085-8120)
- Kun Wang (ORCID: https://orcid.org/0000-0003-2513-768X)
- Tingting Zhao (ORCID: https://orcid.org/0000-0002-1820-7072)
- Longfei Huang (ORCID: https://orcid.org/0000-0002-8347-8223)
- Jingqing Zhang
- Bao-Cai Xing
Institutions
- Second Affiliated Hospital of Inner Mongolia Medical University (CN)
- Inner Mongolia People's Hospital (CN)
- Ministry of Education (ET)
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- World Journal of Hepatology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.4254/wjh.v17.i11.112364
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32